Science Corner
Most edible review sites tell you "studies show" without ever linking a study. We do it differently. Every research claim on EdibleRank is backed by a specific paper. This page collects the studies we reference across the site, with plain-language summaries and direct links to the published research.
What does the research say about edibles for sleep?
Two recent placebo-controlled trials (Bonn-Miller 2024, Saleska 2024) show that 20 to 100mg CBN reduces nighttime awakenings and overall sleep disturbance versus placebo, with effects comparable to 4mg melatonin. CBD alone shows weaker effects on sleep onset. Combination products have not demonstrated additive benefit over CBN alone.
Effects of CBN with and without CBD on sleep quality
Bonn-Miller et al. · Experimental and Clinical Psychopharmacology · 2024
Double-blind, placebo-controlled study of 321 participants with poor sleep. 20mg CBN nightly reduced nighttime awakenings and overall sleep disturbance compared to placebo. Adding CBD did not improve outcomes beyond CBN alone. No impact on daytime fatigue.
Safety and effectiveness of CBN formulations for improving sleep
Saleska, Pauli et al. · Pharmaceuticals (MDPI) · 2024
Placebo-controlled trial of over 1,000 participants testing CBN at 25mg, 50mg, and 100mg doses. All CBN groups showed significant sleep improvement compared to placebo, with no significant difference from 4mg melatonin. CBN was well tolerated with no serious side effects.
Non-psychoactive cannabinoid formulations for sleep improvement
Saleska, Bryant, D'Adamo et al. · Journal of the American Nutrition Association · 2024
Randomized controlled trial of 1,793 adults. All CBD formulations (15mg, with and without CBN) produced significant sleep improvements, though effects did not exceed those of 5mg melatonin. Favorable safety profile with only 12% reporting mild side effects.
What does the research say about CBD for anxiety?
A 2024 meta-analysis of 8 RCTs (316 participants) found a substantial effect of CBD on anxiety symptoms with a large effect size. The 2015 Blessing review across 49 preclinical and clinical studies supports CBD as anxiolytic for generalized anxiety, panic, social anxiety, OCD, and PTSD. Acute dosing has the clearest evidence base.
CBD as a potential treatment for anxiety disorders
Blessing, Steenkamp, Manzanares, Marmar · Neurotherapeutics · 2015
Landmark review of 49 preclinical, clinical, and epidemiological studies. Found strong preclinical evidence supporting CBD for generalized anxiety disorder, panic disorder, social anxiety disorder, OCD, and PTSD. Human evidence supports anxiolytic effects but was limited to acute dosing at the time of publication.
CBD in anxiety disorders: systematic review and meta-analysis
Multiple authors · Psychiatry Research · 2024
Meta-analysis of 8 randomized controlled trials with 316 participants. Found a substantial and significant effect of CBD on anxiety symptoms with a large effect size. Authors call for larger trials but note consistent positive findings across studies.
Mental Health
The differential effects of medicinal cannabis on mental health: A systematic review
Kuhns, Kroon, Cousijn et al. · Clinical Psychology Review · 2025
Systematic review of 49 controlled studies covering anxiety disorders, ADHD, autism, OCD, PTSD, schizophrenia, insomnia, and substance use disorders. Most consistent findings: high-dose CBD provided acute relief in anxiety; CBD + THC combinations alleviated cannabis withdrawal and improved sleep. THC was associated with dose-dependent adverse events and worsened psychosis outcomes in some cases. Authors emphasize that medicinal cannabis may provide short-term relief for certain symptoms but is not a cure and carries real risks.
What does the research say about cannabis edibles for chronic pain?
The 2017 National Academies report found conclusive or substantial evidence that cannabis is effective for chronic pain in adults. A 2025 causal-inference analysis showed medical cannabis users had 2.0 percentage-point fewer urgent care visits, 3.2 fewer ER visits, and 3.5 fewer unhealthy days per month versus non-users.
The Health Effects of Cannabis and Cannabinoids
National Academies of Sciences, Engineering, and Medicine · National Academies Press · 2017
The most comprehensive government review of cannabis research to date. Reviewed over 10,000 studies and reached nearly 100 conclusions. Found "conclusive or substantial evidence" that cannabis is effective for treating chronic pain in adults and for chemotherapy-induced nausea. Also found moderate evidence for improving sleep in certain conditions.
Medical cannabis use and healthcare utilization among chronic pain patients
Multiple authors · PMC / Pharmaceuticals · 2025
Causal inference analysis of medical cannabis patients with chronic pain. Found that medical cannabis use was associated with a 2.0 percentage point reduction in urgent care visits, 3.2 point reduction in ER visits, and 3.5 fewer unhealthy days per month compared to non-users.
No pain, all gain? Longitudinal study of medical cannabis for chronic pain
Gruber, Smith, Schuster, Lukas et al. · Experimental and Clinical Psychopharmacology · 2021
Longitudinal observational study of medical cannabis patients tracked across 3 and 6 months of treatment. Patients exhibited improvements in pain along with better sleep, mood, anxiety, and quality of life. Conventional medication use remained stable. Higher THC exposure was associated with greater pain improvement; higher CBD exposure with greater mood improvement. Treatment-as-usual control patients did not show the same improvements.
MS, Spasticity & Neurological
Therapeutic Effects of Cannabis and Cannabinoids: Spasticity in MS
National Academies of Sciences, Engineering, and Medicine · National Academies Press (NCBI Books) · 2017
Chapter from the National Academies report addressing cannabinoids for MS-related spasticity and spinal cord injury. Conclusion: there is substantial evidence that oral cannabinoids are an effective treatment for improving patient-reported MS spasticity symptoms. Effect size is modest (average reduction of 0.76 units on a 10-point scale) and benefits are clearer on patient-reported scales than on clinician-measured indices like the Modified Ashworth Scale. Evidence is insufficient for spasticity from spinal cord injury.
Comprehensive Reviews
Cannabinoids for Medical Use: Systematic Review and Meta-analysis
Whiting, Wolff, Deshpande et al. · JAMA · 2015
Major JAMA meta-analysis covering 79 randomized trials and 6,462 participants across nausea/vomiting from chemotherapy, HIV/AIDS appetite stimulation, chronic pain, MS spasticity, depression, anxiety, sleep, psychosis, glaucoma, and Tourette syndrome. Found moderate-quality evidence supporting cannabinoids for chronic pain and spasticity, and lower-quality evidence for nausea/vomiting, HIV weight gain, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term adverse events.
Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review
Multiple authors · Annals of Pharmacotherapy · 2020
Comprehensive review of clinical evidence for cannabis-based treatments across Alzheimer's disease, ALS, autism, cancer and cancer-associated adverse effects, seizure disorders, HIV, inflammatory bowel disease, multiple sclerosis, nausea, pain, PTSD, and hospice care. Cannabis-based therapies were generally well tolerated with the most common adverse effects being dizziness, somnolence, dry mouth, nausea, and euphoria. Authors emphasize the need for more high-quality clinical evidence as medical cannabis access continues to expand.
Cannabis, cannabinoids and health: risks and medical benefits
Multiple authors · European Archives of Psychiatry and Clinical Neuroscience (PMC) · 2025
Comprehensive review of cannabis health effects. Confirmed that strongest therapeutic evidence exists for CBD in epilepsy, and THC for spasticity, chronic pain, and chemotherapy nausea. Noted that evidence remains inconclusive for many neuropsychiatric conditions. Highlighted the challenge of standardizing cannabinoid preparations across studies.
Understanding the Risks
The behavioral sequelae of cannabis use in healthy people: A systematic review
Multiple authors · Frontiers in Psychiatry (PMC) · 2021
PRISMA-guideline systematic review of 124 studies from 1990 to 2020 examining cannabis-related adverse behavioral outcomes in subjects without psychiatric or medical co-morbidities. Authors note that adverse outcomes depend on frequency of use, THC potency, age of onset, and cumulative exposure. CBD shows a different profile from THC, with lower receptor affinity, no psychomimetic effects, and evidence of anxiolytic properties. The review emphasizes the role of THC potency and duration of use in modulating risk. Useful context for understanding which use patterns carry meaningful risk and which do not.
Edible cannabis: Five things to know
Stall, Chiu, Redelmeier · CMAJ (Canadian Medical Association Journal) · 2020
Clinical primer on edible cannabis safety. Key facts: edibles have delayed onset (30-90 minutes) and longer duration than inhaled cannabis, which contributes to overconsumption; ED visits attributable to edible cannabis are less frequent than those for inhaled cannabis but are more often associated with acute psychiatric symptoms and cardiovascular complications; ingestion of edibles accounts for three-quarters of all cannabis-related exposures in children, often because of packaging that resembles food. Useful baseline reading on why dosing discipline and safe storage matter.
Feature Essays
Are Edibles Actually Safer Than Smoking for Your Heart?
The newest peer-reviewed data on edibles and cardiovascular risk, including the 2025 UCSF study that separated edible-only users from smokers and found vascular function reductions worse than the smoking cohort.
Read the essay →Endometriosis, Edibles, and Why the Dose Looks So High
Why CB1 receptor density is measurably lower in endometriosis tissue, and what that means for dosing cannabis edibles in chronic pelvic pain.
Read the essay →Know a study we should include?
We're always looking for quality research on cannabinoids and edibles. If you've read something worth adding, send it our way.
hello@ediblerank.comStay in the loop
New rankings, regulatory updates, and dosing tips. Once a week, no spam.